Form 4: Esperion Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Esperion Therapeutics CEO Sheldon L. Koenig sold 14,550 shares of common stock on September 17, 2024, to satisfy tax obligations related to vested restricted stock units.
Summary
- On September 17, 2024, Sheldon L. Koenig, the President and CEO of Esperion Therapeutics, Inc., sold 14,550 shares of the company's common stock.
- The sale was executed at a price of $1.796 per share.
- The purpose of this transaction was to cover tax obligations arising from the vesting of restricted stock units.
- Following the transaction, Koenig directly owns 752,266 shares of Esperion Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an insider stock sale for tax purposes, which is a neutral event.
Industry Context
Form 4 filings are a routine part of insider trading activity and are required by the SEC to ensure transparency. The sale of shares to cover tax obligations is a common practice among executives who receive stock-based compensation.
Stakeholder Impact
- The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is a common practice.
Key Dates
| Date | Description |
|---|---|
| 09/17/2024 | Date of the stock sale transaction. |
| 09/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.